

4. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3, and a pharmaceutically acceptable carrier or diluent.
5. A pharmaceutical composition according to claim 4, which is suitable for oral administration to a subject.
6. A method of preparing a pharmaceutical composition comprising the step of mixing a compound according to any one of claims 1 to 3, and a pharmaceutically acceptable carrier or diluent.
7. A compound according to any one of claims 1 to 3, for use in a method of treatment of the human or animal body by therapy.
- ~~8. A compound according to any one of claims 1 to 3, for use in a method of treatment of a disease or condition that is mediated by CHK1.~~
- ~~9. A compound according to any one of claims 1 to 3, for use in a method of treatment of a disease or condition that is ameliorated by the inhibition of CHK1 kinase function.~~
- ~~108.~~ A compound according to any one of claims 1 to 3, for use in a method of treatment of a proliferative condition.
- ~~149.~~ A compound according to any one of claims 1 to 3, for use in a method of treatment of cancer.
- ~~1210.~~ A compound according to any one of claims 1 to 3, for use in a method of treatment of head cancer; neck cancer; nervous system cancer; brain cancer; neuroblastoma; lung/mediastinum cancer; breast cancer; oesophagus cancer; stomach cancer; liver cancer; biliary tract cancer; pancreatic cancer; small bowel cancer; large bowel cancer; colorectal cancer; gynaecological cancer; genito-urinary cancer; ovarian cancer; thyroid gland cancer; adrenal gland cancer; skin cancer; melanoma; bone sarcoma; soft tissue sarcoma; paediatric malignancy; Hodgkin's disease; non-Hodgkin's lymphoma; myeloma; leukaemia; or metastasis from an unknown primary site.
- ~~1311.~~ A compound according to any one of claims 1 to 3, for use in a method of treatment of lung cancer, breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, melanoma, glioma, or neuroblastoma.

4412. A compound according to any one of claims 1 to 3, for use in a method of treatment of p53 deficient cancer.
- 5 4513. A compound according to any one of claims 1 to 3, for use in a method of treatment of MYC-amplified cancer.
4614. A compound according to any one of claims 1 to 3, for use in a method of treatment of c-MYC-amplified cancer.
- 10 4715. A compound according to any one of claims 1 to 3, for use in a method of treatment of MYCN-amplified cancer.
4816. A compound according to any one of claims 1 to 3, for use in a method of treatment of cancer characterised by overexpression of MYC.
- 15 4917. A compound according to any one of claims 1 to 3, for use in a method of treatment of cancer characterised by overexpression of MYCN.
2018. A compound according to any one of claims 1 to 3, for use in a method of treatment of cancer characterised by overexpression of c-MYC.
- 20 2119. A compound according to any one of claims 1 to 3, for use in a method of treatment of MYCN-amplified neuroblastoma.
- 25 2220. A compound according to any one of claims 1 to 3, for use in a method of treatment of c-MYC-amplified B cell lymphoma.
2321. A compound according to any one of claims 1 to 3, for use in a method of treatment of cancer characterised by increased endogenous replicative stress.
- 30 2422. A compound according to any one of claims 1 to 3, for use in a method of treatment of cancer characterised by increased endogenous activation of CHK1 signalling.
- 35 2523. A compound for use according to any one of claims 7 to 2422, by oral administration.

2624. A compound for use according to any one of claims 7 to 2422, wherein the treatment further comprises treatment with one or more other agents selected from: (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; and (h) an inhibitor of a DNA damage repair enzyme.

~~27. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of a disease or condition that is mediated by CHK1.~~

~~28. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of a disease or condition that is ameliorated by the inhibition of CHK1 kinase function.~~

2925. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of a proliferative condition.

3026. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of cancer.

3127. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of head cancer; neck cancer; nervous system cancer; brain cancer; neuroblastoma; lung/mediastinum cancer; breast cancer; oesophagus cancer; stomach cancer; liver cancer; biliary tract cancer; pancreatic cancer; small bowel cancer; large bowel cancer; colorectal cancer; gynaecological cancer; genito-urinary cancer; ovarian cancer; thyroid gland cancer; adrenal gland cancer; skin cancer; melanoma; bone sarcoma; soft tissue sarcoma; paediatric malignancy; Hodgkin's disease; non-Hodgkin's lymphoma; myeloma; leukaemia; or metastasis from an unknown primary site.

3228. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of lung cancer, breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, melanoma, glioma, or neuroblastoma.

3329. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of p53 deficient cancer.

3430. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of MYC-amplified cancer.

3531. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of c-MYC-amplified cancer.
- 5 3632. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of MYCN-amplified cancer.
3733. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of cancer characterised by overexpression of MYC.
- 10 3834. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of cancer characterised by overexpression of MYCN.
- 15 3935. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of cancer characterised by overexpression of c-MYC.
- 20 4036. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of MYCN-amplified neuroblastoma.
4137. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of c-MYC-amplified B cell lymphoma.
- 25 4238. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of cancer characterised by increased endogenous replicative stress.
- 30 4339. Use of a compound according to any one of claims 1 to 3, in the manufacture of a medicament for the treatment of cancer characterised by increased endogenous activation of CHK1 signalling.
4440. Use according to any one of claims 27-1 to 4339, wherein the medicament is a medicament for oral administration.
- 35 4541. Use according to any one of claims 27-1 to 4339, wherein the treatment further comprises treatment with one or more other agents selected from: (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator;
- 40 (g) an inhibitor of a DNA damage signal transducer; and (h) an inhibitor of a DNA damage repair enzyme.

46. — A method of treatment of a disease or condition that is mediated by CHK1 comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 5 47. — A method of treatment of a disease or condition that is ameliorated by the inhibition of CHK1 kinase function comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 10 48. — A method of treatment of a proliferative condition comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 15 49. — A method of treatment of cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 20 50. — A method of treatment of head cancer; neck cancer; nervous system cancer; brain cancer; neuroblastoma; lung/mediastinum cancer; breast cancer; oesophagus cancer; stomach cancer; liver cancer; biliary tract cancer; pancreatic cancer; small bowel cancer; large bowel cancer; colorectal cancer; gynaecological cancer; genito-urinary cancer; ovarian cancer; thyroid gland cancer; adrenal gland cancer; skin cancer; melanoma; bone sarcoma; soft tissue sarcoma; paediatric malignancy; Hodgkin's disease; non-Hodgkin's lymphoma; myeloma; leukaemia; 25 or metastasis from an unknown primary site, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 30 51. — A method of treatment of lung cancer, breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, melanoma, glioma, or neuroblastoma comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 35 52. — A method of treatment of MYC-amplified cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 40 53. — A method of treatment of c-MYC-amplified cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.

54. — A method of treatment of MYCN-amplified cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 5 55. — A method of treatment of cancer characterised by overexpression of MYC comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 10 56. — A method of treatment of cancer characterised by overexpression of MYCN comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 15 57. — A method of treatment of cancer characterised by overexpression of c-MYC comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 20 58. — A method of treatment of MYCN-amplified neuroblastoma comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 25 59. — A method of treatment of c-MYC-amplified B-cell lymphoma comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 30 60. — A method of treatment of cancer characterised by increased endogenous replicative stress comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
- 35 61. — A method of treatment of cancer characterised by increased endogenous activation of CHK1 signalling comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to any one of claims 1 to 3.
62. — A method according to any one of claims 46 to 61, wherein said administering is orally administering.

63. ~~A method according to any one of claims 46 to 61, wherein the treatment further comprises administering to the subject one or more other agents selected from: (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; and (h) an inhibitor of a DNA damage repair enzyme.~~
- 5
6442. A method of inhibiting CHK1 kinase function, *in vitro* ~~or in vivo~~, comprising contacting the cell with an effective amount of a compound according to any one of claims 1 to 3.
- 10
6543. A method of inhibiting CHK1 kinase function in a cell, *in vitro* ~~or in vivo~~, comprising contacting the cell with an effective amount of a compound according to any one of claims 1 to 3.
- 15
6644. A method of inhibiting cell proliferation, inhibiting cell cycle progression, promoting cell apoptosis, or a combination of one or more these, *in vitro* ~~or in vivo~~, comprising contacting the cell with an effective amount of a compound according to any one of claims 1 to 3.
- 20